TY - JOUR
T1 - American Association of Physicists in Medicine Task Group 263
T2 - Standardizing Nomenclatures in Radiation Oncology
AU - Mayo, Charles S.
AU - Moran, Jean M.
AU - Bosch, Walter
AU - Xiao, Ying
AU - McNutt, Todd
AU - Popple, Richard
AU - Michalski, Jeff
AU - Feng, Mary
AU - Marks, Lawrence B.
AU - Fuller, Clifton D.
AU - Yorke, Ellen
AU - Palta, Jatinder
AU - Gabriel, Peter E.
AU - Molineu, Andrea
AU - Matuszak, Martha M.
AU - Covington, Elizabeth
AU - Masi, Kathryn
AU - Richardson, Susan L.
AU - Ritter, Timothy
AU - Morgas, Tomasz
AU - Flampouri, Stella
AU - Santanam, Lakshmi
AU - Moore, Joseph A.
AU - Purdie, Thomas G.
AU - Miller, Robert C.
AU - Hurkmans, Coen
AU - Adams, Judy
AU - Jackie Wu, Qing Rong
AU - Fox, Colleen J.
AU - Siochi, Ramon Alfredo
AU - Brown, Norman L.
AU - Verbakel, Wilko
AU - Archambault, Yves
AU - Chmura, Steven J.
AU - Dekker, Andre L.
AU - Eagle, Don G.
AU - Fitzgerald, Thomas J.
AU - Hong, Theodore
AU - Kapoor, Rishabh
AU - Lansing, Beth
AU - Jolly, Shruti
AU - Napolitano, Mary E.
AU - Percy, James
AU - Rose, Mark S.
AU - Siddiqui, Salim
AU - Schadt, Christof
AU - Simon, William E.
AU - Straube, William L.
AU - St. James, Sara T.
AU - Ulin, Kenneth
AU - Yom, Sue S.
AU - Yock, Torunn I.
N1 - Funding Information:
Conflict of interest: Dr Molineu reports grants from the National Cancer Institute, during the conduct of the study. Dr Matuszak reports grants from Varian Medical Systems, outside the submitted work. Dr Napolitano reports other support from IBA Dosimetry, outside the submitted work. Ms Lansing is an employee of Eleckta Corporation. Dr Bosch reports grants from the US National Institutes of Health, during the conduct of the study. Dr Bosch reports grants from the US National Institutes of Health, during the conduct of the study.
Publisher Copyright:
© 2017 The Authors
PY - 2018/3/15
Y1 - 2018/3/15
N2 - A substantial barrier to the single- and multi-institutional aggregation of data to supporting clinical trials, practice quality improvement efforts, and development of big data analytics resource systems is the lack of standardized nomenclatures for expressing dosimetric data. To address this issue, the American Association of Physicists in Medicine (AAPM) Task Group 263 was charged with providing nomenclature guidelines and values in radiation oncology for use in clinical trials, data-pooling initiatives, population-based studies, and routine clinical care by standardizing: (1) structure names across image processing and treatment planning system platforms; (2) nomenclature for dosimetric data (eg, dose–volume histogram [DVH]-based metrics); (3) templates for clinical trial groups and users of an initial subset of software platforms to facilitate adoption of the standards; (4) formalism for nomenclature schema, which can accommodate the addition of other structures defined in the future. A multisociety, multidisciplinary, multinational group of 57 members representing stake holders ranging from large academic centers to community clinics and vendors was assembled, including physicists, physicians, dosimetrists, and vendors. The stakeholder groups represented in the membership included the AAPM, American Society for Radiation Oncology (ASTRO), NRG Oncology, European Society for Radiation Oncology (ESTRO), Radiation Therapy Oncology Group (RTOG), Children's Oncology Group (COG), Integrating Healthcare Enterprise in Radiation Oncology (IHE-RO), and Digital Imaging and Communications in Medicine working group (DICOM WG); A nomenclature system for target and organ at risk volumes and DVH nomenclature was developed and piloted to demonstrate viability across a range of clinics and within the framework of clinical trials. The final report was approved by AAPM in October 2017. The approval process included review by 8 AAPM committees, with additional review by ASTRO, European Society for Radiation Oncology (ESTRO), and American Association of Medical Dosimetrists (AAMD). This Executive Summary of the report highlights the key recommendations for clinical practice, research, and trials.
AB - A substantial barrier to the single- and multi-institutional aggregation of data to supporting clinical trials, practice quality improvement efforts, and development of big data analytics resource systems is the lack of standardized nomenclatures for expressing dosimetric data. To address this issue, the American Association of Physicists in Medicine (AAPM) Task Group 263 was charged with providing nomenclature guidelines and values in radiation oncology for use in clinical trials, data-pooling initiatives, population-based studies, and routine clinical care by standardizing: (1) structure names across image processing and treatment planning system platforms; (2) nomenclature for dosimetric data (eg, dose–volume histogram [DVH]-based metrics); (3) templates for clinical trial groups and users of an initial subset of software platforms to facilitate adoption of the standards; (4) formalism for nomenclature schema, which can accommodate the addition of other structures defined in the future. A multisociety, multidisciplinary, multinational group of 57 members representing stake holders ranging from large academic centers to community clinics and vendors was assembled, including physicists, physicians, dosimetrists, and vendors. The stakeholder groups represented in the membership included the AAPM, American Society for Radiation Oncology (ASTRO), NRG Oncology, European Society for Radiation Oncology (ESTRO), Radiation Therapy Oncology Group (RTOG), Children's Oncology Group (COG), Integrating Healthcare Enterprise in Radiation Oncology (IHE-RO), and Digital Imaging and Communications in Medicine working group (DICOM WG); A nomenclature system for target and organ at risk volumes and DVH nomenclature was developed and piloted to demonstrate viability across a range of clinics and within the framework of clinical trials. The final report was approved by AAPM in October 2017. The approval process included review by 8 AAPM committees, with additional review by ASTRO, European Society for Radiation Oncology (ESTRO), and American Association of Medical Dosimetrists (AAMD). This Executive Summary of the report highlights the key recommendations for clinical practice, research, and trials.
UR - http://www.scopus.com/inward/record.url?scp=85042512323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042512323&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2017.12.013
DO - 10.1016/j.ijrobp.2017.12.013
M3 - Review article
C2 - 29485047
AN - SCOPUS:85042512323
SN - 0360-3016
VL - 100
SP - 1057
EP - 1066
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 4
ER -